An experimental cancer drug was used to clear away errant inflammatory cells in a mouse model for Alzheimer's, demonstrating potential for improving cognition even though it had no impact on the amyloid beta clusters many believe cause the memory-wasting disease.
A group of scientists from the University of Cambridge, Lund University and the University of Groningen concluded that the lymphoma drug bexarotene may interrupt the first step in the process that leads to Alzheimer's. The conclusion was reached after studying the drug on worm models for the disease. And the resulting headlines in U.K. newspapers about a potential cure for Alzheimer's led to considerable hooting on Twitter, where it was called out as another example of hyping preclinical studies.
Johnson & Johnson sees big things ahead for California's NeuroVision, so it's expanding its partnership with the company. The move gives NeuroVision a boost as it looks to grab a bigger piece of the market for its Alzheimer's eye-imaging diagnostic.
Singapore-based TauRx is expected to complete global Phase III trials this year for its Alzheimer's candidate, tau aggregation inhibitor LMTX, that will either start a new chapter in treatment or join a long list of flops.
Tech titans like Google, Samsung and Apple have clear med tech ambitions. Now a food giant is trying to grab a slice of the pie. The Nestlé Institute of Health Sciences SA seeks to deploy its proprietary diagnostic technology platform to develop an assay for the early detection of Alzheimer's.
By studying a group of outliers in a Colombian family known for the prevalence of early-onset Alzheimer's, investigators at UC Santa Barbara believe they may have fingered a new drug target that could delay the disease by a decade or more.
As scientists zero in on quick, inexpensive ways to screen for Alzheimer's, a New York startup is developing a video game-like tool for catching early signs of the disease.
With the Alzheimer's Association International Conference underway in Washington, DC, there's been a big focus on the late-stage pipeline. But scientists at NYU Langone Medical Center were focused on new animal data that they say supports work on a new group of antibodies that can tackle two of the chief culprits behind the brain-damaging disease.
Universities regularly woo top scientists from rival institutions, recruiting not only high-profile individuals but their lab teams as well in the hope of bagging promising science and the millions in federal funding that go along with it. But in a rare confrontation, UC San Diego has sued USC and research scientist Paul Aisen for an alleged conspiracy to purloin data and investigators involved in prominent Alzheimer's research work.
Alzheimer's has long been one of the most contentious fields in drug development. As one drug after the next failed in late-stage clinical studies, drug developers have been moving further and further upstream in the disease process to see if they can more effectively blunt the progress of this disease in early-stage patients.